SXTP — 60 DEGREES PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1946563 ·
Last close
$0.53
Market Cap
$1.88M
52W High
$8.62
52W Low
$0.46
ADV30
687,422
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 207,898 56,798 -2,271,102 -2,264,526 4,282,694 1,022,606 1,754,271
Mar 2026 162,092 76,377 -2,094,961 -2,089,214 6,763,346 3,337,760 2,018,867
Dec 2025 303,385 182,703 -1,917,351 -1,438,559 5,366,211 1,510,065 1,986,795
Sep 2025 437,602 -100,088 -2,325,525 -2,316,324 6,689,344 4,115,779 2,342,386

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-8,774,808
Investing CF
$-288,342
Financing CF
$8,110,544
CapEx
$-288,342
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.71
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-52,246,855
Inventory
$877,945
Receivables
$567,040
ST Investments
$0
EBIT TTM
$-8,105,812
Pretax Income TTM
$-8,113,398
Interest Exp TTM
$7,586
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,214,931
EBITDA
$-8,504,303
Free Cash Flow
$-6,081,180
Enterprise Value
$11,775,539
Total Cash
$1,022,606
Total Debt
$151,179
Shares Out
3,516,988
Trailing EPS
$-2.67
Book Value
$-2.62
ROE
-332.9%
ROA
-127.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,005,471 -7,758,579 -7,365,158 5,366,211 1,986,795 3,463,177 -6,849,022
Dec 2024 607,574 -9,715,181 -7,947,107 5,759,345 1,804,339 4,035,600 -5,648,088
Dec 2023 253,573 -5,154,583 -3,765,702 7,783,771 2,985,675 4,870,134 -4,542,910
Dec 2022 223,208 -1,750,445 -6,181,720 1,297,206 25,446,266 -23,576,740 -1,009,980

TTM Snapshot

Revenues TTM
$1,110,977
NetIncome TTM
$-8,108,623
OpCashFlow TTM
—
Assets (Latest)
$4,282,694
Forward EPS
$-3.58

Peers — same industry

TickerNameMarket CapLastDaily %
ACUT Accustem Sciences Inc. $1.90M $0.12 —
XRTX XORTX Therapeutics Inc. $1.93M $1.06 —
PPCB Propanc Biopharma, Inc. $1.94M $1.88 —
JAGX Jaguar Health, Inc. $1.96M $0.38 —
JUNS JUPITER NEUROSCIENCES, INC. $2.00M $1.52 —

News headlines (Yahoo Finance, 1h cache)

Join 60 Degrees Pharmaceuticals' Live Investor Webinar: Advancing Tafenoquine for Babesiosis While Expanding ARAKODA(R) Commercialization
2026-11-04 21:15 · Yahoo
60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome
2026-10-28 12:30 · Yahoo
60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
2026-10-27 12:06 · Yahoo
60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting
2026-10-06 14:44 · Yahoo
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
2026-10-06 12:10 · Yahoo
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-10-02 13:00 · Yahoo
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
2026-10-01 12:03 · Yahoo
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
2026-08-14 19:47 · Yahoo
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
2026-07-08 12:01 · Yahoo
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
2026-07-01 12:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.